Nuvation Bio (NUVB) is back in focus after signing an exclusive license and collaboration agreement with Eisai for taletrectinib, bringing immediate cash payments and potential milestones tied to global expansion beyond its existing markets.

Despite the Eisai agreement and recent conference visibility, Nuvation Bio’s share price return has seen a 27.34% fall over the past week and a 29.10% decline over the past month. At the same time, the 90 day share price return of 80.06% and 1 year total shareholder return of 141.73% suggest earlier momentum that has cooled more recently.

If this kind of biotech news has your attention, it could be a good moment to scan healthcare stocks and see which other names in the sector fit your criteria.

With the stock up 80.06% over 90 days but down sharply over the past month, and with a price target implying a discount to where analysts sit, it is fair to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Price to Book of 6.5x: Is It Justified?

At a last close of US$6.14, Nuvation Bio is trading on a P/B ratio of 6.5x, which screens as good value versus some peers but expensive versus the wider US pharmaceuticals group.

The P/B ratio compares the company’s market value to its reported net assets. This can be a common reference point for clinical stage biopharma where earnings are still negative. For Nuvation Bio, this means investors are paying a multiple of the current book value despite the business still reporting a net loss of US$217.48 million on revenue of US$26.748 million.

Simply Wall St’s model flags two contrasting signals. On one hand, Nuvation Bio is described as good value versus peer companies on a P/B of 6.5x compared with a peer average of 11.7x, implying the market is assigning a lower premium than some closer comparables. On the other hand, that same 6.5x sits above the broader US pharmaceuticals industry average of 2.6x, suggesting the wider sector trades on a far lower multiple of book value.

Result: Price to book of 6.5x (ABOUT RIGHT)

However, you still need to weigh clinical and execution risk around taletrectinib and other pipeline assets, along with ongoing losses of US$217.48 million.

Another View: Our DCF Model Paints A Different Picture

If you switch from the P/B lens to the Simply Wall St DCF model, the story changes sharply. At US$6.14, the shares are indicated as trading around 85.5% below an estimated fair value of US$42.40. This suggests the market is pricing in a lot of uncertainty around future cash flows.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Nuvation Bio for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 868 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Nuvation Bio Narrative

If you look at this and think you would reach a different conclusion, or simply prefer to work from your own checks, you can build a personalized view in just a few minutes with Do it your way

A great starting point for your Nuvation Bio research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If you are serious about broadening your watchlist, do not stop at one stock. Use the Simply Wall St Screener to quickly surface new, high conviction ideas tailored to you.

• Spot potential value by scanning these 868 undervalued stocks based on cash flows that might line up better with the price and quality mix you want.
• Ride major tech themes by checking out these 24 AI penny stocks that are tied to artificial intelligence trends shaping many businesses.
• Tap into digital assets by reviewing these 80 cryptocurrency and blockchain stocks that connect traditional markets with cryptocurrency and blockchain exposure.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.